Shawver Laura insider trades
Shawver Laura has filed 24 Form 4s with the SEC that we hold, for ARS Pharmaceuticals, Inc. (SPRY) (Director), Relay Therapeutics, Inc. (RLAY) (Director) and Nkarta, Inc. (NKTX) (Director). Across all of them we count 0 purchases worth $0 and 23 sales worth $8.6M reported on Form 4. None of these purchases or sales is dated in the last 12 months. The largest single trade was a sale of 96,343 shares of ARS Pharmaceuticals, Inc. worth $1.3M, dated 2024-12-02. The first filing on our record is dated 2022-02-02 and the latest 2026-06-26.
ARS Pharmaceuticals, Inc. (SPRY)
| Trade date | Code | Shares | Value as filed | Filed |
|---|---|---|---|---|
| 2022-11-09 | S, sale reported on Form 4 | 43,896 | $201.0K | 2023-05-10 |
| 2023-05-08 | S, sale reported on Form 4 | 57,100 | $351.7K | 2023-05-10 |
| 2023-05-09 | S, sale reported on Form 4 | 42,900 | $227.8K | 2023-05-10 |
| 2023-06-01 | S, sale reported on Form 4 | 73,059 | $496.8K | 2023-06-02 |
| 2023-06-02 | S, sale reported on Form 4 | 26,941 | $187.2K | 2023-06-02 |
| 2023-07-03 | S, sale reported on Form 4 | 26,520 | $178.5K | 2023-07-06 |
| 2023-07-05 | S, sale reported on Form 4 | 31,112 | $199.4K | 2023-07-06 |
| 2023-07-06 | S, sale reported on Form 4 | 33,510 | $212.5K | 2023-07-06 |
| 2023-07-07 | S, sale reported on Form 4 | 8,858 | $56.3K | 2023-07-07 |
| 2023-08-01 | S, sale reported on Form 4 | 18,715 | $134.6K | 2023-08-03 |
| 2023-08-02 | S, sale reported on Form 4 | 36,281 | $257.2K | 2023-08-03 |
| 2023-08-03 | S, sale reported on Form 4 | 26,107 | $183.0K | 2023-08-07 |
| 2023-08-04 | S, sale reported on Form 4 | 18,897 | $133.4K | 2023-08-07 |
| 2023-09-01 | S, sale reported on Form 4 | 100,000 | $771.0K | 2023-09-05 |
| 2024-12-02 | S, sale reported on Form 4 | 96,343 | $1.3M | 2024-12-04 |
| 2024-12-02 | S, sale reported on Form 4 | 901 | $12.9K | 2024-12-04 |
| 2024-12-03 | S, sale reported on Form 4 | 87,984 | $1.2M | 2024-12-04 |
| 2024-12-04 | S, sale reported on Form 4 | 14,772 | $203.1K | 2024-12-04 |
| 2025-01-06 | S, sale reported on Form 4 | 50,000 | $555.0K | 2025-01-07 |
| 2025-02-03 | S, sale reported on Form 4 | 50,000 | $615.5K | 2025-02-04 |
| 2025-03-05 | S, sale reported on Form 4 | 400 | $4.4K | 2025-03-07 |
| 2025-03-06 | S, sale reported on Form 4 | 49,600 | $556.0K | 2025-03-07 |
| 2025-04-07 | S, sale reported on Form 4 | 50,002 | $615.0K | 2025-04-08 |
Relay Therapeutics, Inc. (RLAY)
No purchase or sale of common stock reported here; these filings cover grants, option exercises or other codes.
Nkarta, Inc. (NKTX)
No purchase or sale of common stock reported here; these filings cover grants, option exercises or other codes.
Counted from the Form 4 filings this reporting owner (SEC CIK 1551891) filed on EDGAR. Values are the transaction values as filed. See every filing on EDGAR, or browse insider buying and today's insider purchases.
Source: U.S. Securities and Exchange Commission (EDGAR) and other official
government data · Updated 2026-10-12 ·
For informational purposes only, not investment advice.
Privacy · Terms